SIRPA and neoplasm: The combination of AB21 containing an inactive Fc-domain with rituximab significantly improved anti-tumor activity compared to rituximab alone (Fig. 2c and Additional file 1: Fig. S2), consistent with the known impact of CD47–SIRPα antagonism on potentiating responses to antitumor antibody therapy [13, 31].